Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 6/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18549277 | 1.00 | PPARA (0.45) | PPARAPPARGPPARDKIF11CTSK | |
| SCHEMBL30519129 | 0.88 | ADORA1 (0.46) | PPARAPPARGPPARDKIF11CTSK | |
| SCHEMBL30519267 | 0.88 | ADORA1 (0.46) | PPARAPPARGPPARDKIF11CTSK | |
| SCHEMBL906631 | 0.87 | CTSK (0.48) | PPARAPPARGPPARDKIF11CTSK | |
| SCHEMBL5276867 | 0.87 | CTSK (0.48) | PPARAPPARGPPARDKIF11CTSK | |
| SCHEMBL2947993 | 0.83 | PPARA (0.46) | PPARAPPARGPPARDCTSKATM | |
| SCHEMBL2947991 | 0.83 | PPARA (0.46) | PPARAPPARGPPARDCTSKATM | |
| SCHEMBL2675628 | 0.83 | PPARA (0.46) | PPARAPPARGPPARDCTSKATM | |
| SCHEMBL2675632 | 0.83 | PPARA (0.46) | PPARAPPARGPPARDCTSKATM | |
| SCHEMBL21084961 | 0.82 | PPARA (0.61) | PPARAPPARGPPARDKIF11ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718645-B2 | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3107919-B1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIV FLORIDA (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200317732-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-10-08 | — | — | US | disclosed |
| US-20190241611-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-08-08 | — | — | US | disclosed |
| US-20170057996-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718645-B2 | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment | NFATC1, MCL1, ICOS | PPARA 2302/4885PPARG 1415/4885PPARD 3061/4885 |
| US-20200317732-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | NFATC1, MCL1, ICOS | PPARA 2302/4885PPARG 1415/4885PPARD 3061/4885 |
| US-20170057996-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | NFATC1, MCL1, ICOS | PPARA 2302/4885PPARG 1415/4885PPARD 3061/4885 |
| US-20190241611-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | NFATC1, MCL1, ICOS | PPARA 2302/4885PPARG 1415/4885PPARD 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.